Par Adds To HIV Portfolio With Immtech’s Pafuramidine
This article was originally published in The Pink Sheet Daily
Executive Summary
Par is projecting a late 2007 or early 2008 NDA submission for pneumocystis pneumonia in AIDS, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Immtech, Par Halt Pafuramidine Development For HIV
Decision follows abnormal kidney function events in Phase I trial, December FDA clinical hold.
Immtech, Par Halt Pafuramidine Development For HIV
Decision follows abnormal kidney function events in Phase I trial, December FDA clinical hold.
Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users
Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.